Clearside Biomedical Company Description
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space.
The company offers XIPERE, a triamcinolone acetonide injectable suspension for the treatment of macular edema associated with uveitis.
It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which has completed Phase 2 clinical trial to treat wet AMD.
The company has a collaboration with bausch + lomb ireland limited, Arctic Vision (Hong Kong) Limited, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences, Inc. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.
On November 23, 2025, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
| Country | United States |
| Founded | 2011 |
| Industry | Pharmaceutical Preparations |
| Employees | 32 |
| CEO | George Lasezkay |
Contact Details
Address: 900 North Point Parkway Alpharetta, Delaware 30005 United States | |
| Phone | 678 270 3631 |
| Website | clearsidebio.com |
Stock Details
| Ticker Symbol | CLSDQ |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| George Lasezkay | Chief Executive Officer |
| Charles Deignan | Chief Financial Officer |
| Jenny Kobin | Head of Investor Relations |